UM

浏览/检索结果: 共8条,第1-8条 帮助

已选(0)清除 条数/页:   排序方式:
Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes Journal article
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2018,Volume: 14,Issue: 2,Page: 204-216
作者:  Yang, Zheng;  Tam, Kin Yip
收藏  |  浏览/下载:12/0  |  提交时间:2018/10/30
Combination  Egfr-tki  Nsclc  Chemotherapy  Targeted Therapy  Immunotherapy  
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies Journal article
CANCER LETTERS, 2018,Volume: 420,Page: 242-246
作者:  Tang, Zheng-Hai;  Lu, Jin-Jian
收藏  |  浏览/下载:12/0  |  提交时间:2018/10/30
Osimertinib  Azd9291  Egfr Tki  Resistant Mechanisms  Therapeutic Strategies  
Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells Journal article
Anti-Cancer Agents in Medicinal Chemistry, 2018,Volume: 18,Issue: 4,Page: 550-555
作者:  Tang Z.-H.;  Su M.-X.;  Guo X.;  Jiang X.-M.;  Jia L.;  Chen X.;  Lu J.-J.
收藏  |  浏览/下载:4/0  |  提交时间:2018/12/28
Azd9291  Egfr  Ire1α  Lune Cancer  Nsclc  Osimertinib  
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2017,Volume: 815,Page: 80-87
作者:  Yang, Zheng;  Hu, Xiaohui;  Zhang, Shaolin;  Zhang, Wen;  Tam, Kin Yip
收藏  |  浏览/下载:29/0  |  提交时间:2018/10/30
Synergism  Dichloroacetophenone  Dichloroacetate  Egfr  Apoptosis  Acquired Resistance  
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells Journal article
ACTA PHARMACOLOGICA SINICA, 2017,Volume: 38,Issue: 11,Page: 1512-1520
作者:  Jiang, Xiao-Ming;  Xu, Yu-Lian;  Huang, Mu-Yang;  Zhang, Le-Le;  Su, Min-Xia;  Chen, Xiuping;  Lu, Jin-Jian
收藏  |  浏览/下载:16/0  |  提交时间:2018/10/30
Non-small Cell Lung Cancer  Egfr  Osimertinib  Pd-l1  Ubiquitin-proteasome System  Mg-132  Bortezomib  Gsk3 Beta  Licl  
Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor Journal article
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017,Volume: 330,Page: 65-73
作者:  Li, Ting;  Chen, Xin;  Dai, Xiao-Yang;  Wei, Bin;  Weng, Qin-Jie;  Chen, Xiuping;  Ouyang, De-Fang;  Yan, Ru;  Huang, Zhang-Jian;  Jiang, Hu-Lin;  Zhu, Hong;  Lu, Jin-Jian
收藏  |  浏览/下载:9/0  |  提交时间:2018/10/30
Everolimus  Platycodin d  Hsp90  Cdc37  Egfr  Igf1r  
Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line Journal article
Oncotarget, 2016,Volume: 7,Issue: 49,Page: 81598-81610
作者:  Tang Z.-H.;  Jiang X.-M.;  Guo X.;  Fong C.M.V.;  Chen X.;  Lu J.-J.
收藏  |  浏览/下载:6/0  |  提交时间:2018/12/28
Azd9291  Egfr  Navitoclax  Nsclc  Osimertinib  
IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities Journal article
Cancer Letters, 2013,Volume: 340,Issue: 1,Page: 88
作者:  Li Y.-B.;  Wang Z.-Q.;  Yan X.;  Chen M.-W.;  Bao J.-L.;  Wu G.-S.;  Ge Z.-M.;  Zhou D.-M.;  Wang Y.-T.;  Li R.-T.
收藏  |  浏览/下载:3/0  |  提交时间:2018/10/31
Angiogenesis  Breast Cancer  Egfr  Irreversible Tki